Loading
Proposed: a TROP2 PET scan to choose between three TROP2 ADCs and predict who will respond, since tissue staining has not worked.
This proposed diagnostic-therapeutic pairing uses TROP2 PET to choose among the TROP2 Antibody-drug conjugate (ADC) agents Sacituzumab govitecan, Datopotamab deruxtecan and Sacituzumab tirumotecan and to predict who will respond, since tissue staining has not worked. The rationale is that ASCENT showed benefit regardless of TROP2 immunohistochemistry, possibly because one archival sample misses heterogeneity and dynamics that whole-body PET could capture. First-in-human TROP2 tracers exist (89Zr antibodies, 68Ga and 18F nanobodies) but there are no outcome data yet, so the evidence is concept plus phase 1 imaging. It would also allow monitoring of antigen loss on progression and rational ADC sequencing in Triple-negative breast cancer (TNBC) and Non-small-cell lung cancer.
Shares TROP2, Datopotamab deruxtecan, Sacituzumab tirumotecan, Sacituzumab govitecan.
Shares TROP2 PET to choose and sequence TROP2 ADCs, TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, Datopotamab deruxtecan, Antibody-drug conjugate (ADC).
Shares TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, Datopotamab deruxtecan, Sacituzumab govitecan, Triple-negative breast cancer (TNBC).
Shares Datopotamab deruxtecan, Sacituzumab govitecan, Antibody-drug conjugate (ADC), Triple-negative breast cancer (TNBC).
Shares Datopotamab deruxtecan, Antibody-drug conjugate (ADC), Triple-negative breast cancer (TNBC), Non-small-cell lung cancer.
Shares TROP2, Datopotamab deruxtecan, Sacituzumab govitecan, Antibody-drug conjugate (ADC).
Shares TROP2 PET, TROP2, Antibody-drug conjugate (ADC), Triple-negative breast cancer (TNBC).
Shares TROP2 PET, TROP2, Triple-negative breast cancer (TNBC).